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Abstract
Background: Medication therapy is commonly accepted as the initial treatment of trigeminal neuralgia (TN). 
Microvascular decompression (MVD) is the surgical treatment with the highest efficacy, but is considered as last tier 
therapy for patients with medication refractory pain or for those with unbearable side effects. The aim of this study was 
to investigate the association of symptom duration on outcome.
Methods: A retrospective study was conducted from 2001 through 2012. Patients were categorized according to 
Burchiel’s “Classification scheme for facial pains commonly encountered in neurosurgical practice”. Demographical, 
disease and treatment data as well as surgical data including complications and outcome were recorded and analyzed.
Results: In total, 65 patients were included. Distribution of diagnoses was as follows: TN type 1 (>50% episodic pain) 
n=54, TN type 2 (>50% constant pain) n=4, neuropathic TN n=1, symptomatic TN due to multiple sclerosis n=3, post herpetic 
n=2. Onset of disease to surgery was on average 7 years (<1-21 years). Shorter time from disease onset to surgery had 
a statistically significant association with a pain-free outcome in only TN type 1 patients (6 vs. 13 years, p=0.01). Overall 
success rate in TN1 was 88.9%. Overall mortality and morbidity rate were 3%. Overall complication rate was 13.5%.
Conclusion: Earlier MVD was significantly associated with better outcome. Patients should be informed about the 
option of MVD at an early stage of disease.
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Introduction
As a mean to re-establish human capacity and human function in 
society, rehabilitation is related to an effort to restore for a good condition, 
including restoring function and re-integrating to communities [1,2]. 
Psychological rehabilitation of terrorism offenders focuses on character 
building and well-being, in order to have more peaceful state of mind and 
favorable attitude to successfully contribute to society [1]. Orientation of 
psychological development activities is giving opportunity to offenders 
to transform into more positive individuals [3].
Practically, there are two types of rehabilitation to terrorism 
offenders. The first includes isolation techniques (‘exclusiveness’), 
which would isolate terrorism offenders in some special circumstances 
[4,5]. The fundamental reason for exclusiveness is related to the 
prevention of the spread of ideology that justifies violence. The 
use of sacred texts to justify violence [6,7] and the wide range of 
terrorism network are seen to be hazardous [8,9]. The second type 
of rehabilitation is related to allowing terrorism offenders to blend 
or meet with general criminal inmates or visitors (e.g. family) under 
certain circumstances (“inclusiveness”), in order to encounter Humans 
Rights concern [10]. Both exclusiveness and inclusiveness include 
counseling session, assistance (e.g. programs for family), exposure 
to new learning experiences, dialogues with several favorable source 
persons, and empowerment facilitation [11-17]. 
To address whether inclusiveness and exclusiveness is the best 
application in rehabilitating the psychology of terrorism offenders, this 
research will examine steps in rehabilitating religious terrorism offenders, 
psychological transformation process and observed positive behavioral 
changes in religious terrorism offenders. The study aims to figure out the 
effective implementations of inclusiveness and exclusiveness on religious 
terrorism offenders at prisons. As the discussion about rehabilitating 
terrorism offenders will always be linked to the motivation of terrorism, 
this study will review motives of religious terrorism offenders, causes of 
religious terrorism, and shared process of psychological transformation 
within religious terrorism offenders.
Materials and Methods
A retrospective study was conducted including all patients treated 
by MVD for TN in our institution from 2001 to 2012. Patients were 
categorized according to Burchiel’s [18] “Classification scheme for facial 
pains commonly used encountered in neurosurgical practice” (Table 1). All 
patients signed the local official informed consent for the surgical procedure. 
Three surgeons performed the procedure, which consisted of 
decompression accordingly to previous descriptions [19-21]. In 
short, a detailed exploration of the cisternal portion of the nerve was 
conducted to avoid missing multiple vessel conflicts. Teflon (Johnson 
& Johnson, Ltd.) was used as interposition material between the vessels 
Diagnosis History N=65
Trigeminal neuralgia, Type 1 >50% episodic pain (spontaneous onset) 55
Trigeminal neuralgia, Type 2 >50% constant pain (spontaneous onset) 4
Trigeminal neuropathic pain Unintentional, incidental trauma (injury) 1
Trigeminal deafferentation pain Intentional deafferentation (injury) 0
Symptomatic trigeminal neuralgia Multiple sclerosis 3
Table 1: Distribution of diagnoses according to Burchiel’s [18] classification of facial 
pain.
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and the trigeminal nerve. Avoiding contact between Teflon® and 
nerve, as recommended by Sindou et al. [20], was not possible in all 
cases [22]. Clinical characteristics, disease specific, procedural specific 
data and prior treatments were recorded. An outpatient checkup was 
conducted in all patients 4-5 weeks postoperatively. Further follow-
up was at variable time points. Long-term outcome was recorded as 
follows for pain: pain free, improved, unchanged, worse. A worsening 
due to complications or other reasons and death were recorded 
separately. Special attention was given to postoperative complications, 
i.e., cerebellar symptoms, facial hypoesthesia, facial palsy, hearing loss, 
tinnitus, persisting wound pain (>3 months), persistent cerebrospinal 
fluid (CSF) fistula, wound infection and postoperative hemorrhage.
The outcome groups were analyzed for time from disease onset to 
surgery using the t-tests and linear regression. Statistical analysis was 
performed with “R” software version 2.12.2 (The R Foundation for 
Statistical Computing).
Results
Clinical characteristics
A total of 65 patients have undergone 74 MVDs. One patient was 
operated bilaterally. Thirty-five patients were female. Distribution of 
diagnoses is shown in Table 1. Mean age at onset of disease was 57 years 
(range 26 to 79). Mean age at the time of surgery was 64 years (range 
30-84). As for the involved trigeminal segments, the first branch (V1) 
was involved in 23 cases (35.4%), the V2 in 49 cases (75.4%) and the 
V3 in 23 (35.4%). In 3 patients (4.6%) all branches were involved, in 13 
patients (20%) the branches V2 and V3 and in 13 (20%) the branches 
V1 and V2.
Treatment
Preoperative invasive procedures for trigeminal neuralgia were 
conducted in 9 patients (13.8%); 6 (9.2%) received a glycerol rhizotomy and 
3 (4.6%) a thermorhizotomy. These patients were older than patients that 
did receive only medical therapy (mean age 65 and 56 years, respectively). 
One of these pre-treated patients did not improve postoperatively, the other 
one died of pneumonia. Mean duration from onset of symptoms to MVD 
was 7 years (range 3.5 months-21 years). During all operations a conflicting 
vessel, a vein, an artery or both, was identified. 
Complications
Complications were noted in 10 patients and 74 operations leading to an 
overall complication rate of (13.5%). One patient suffered from a superficial 
wound infection (1.35%), which was treated with antibiotics. Four patients 
developed a persistent CSF fistula (5.4%), which was all diagnosed by 
rhinorrhea. All these patients were re-operated without reopening the 
intradural space. Other complications consisted of temporary hearing 
reduction due to haematotympanum (n=1, 1.35%), permanent one-sided 
hearing loss (n=1, 1.35%) and permanent facial hypaesthesia (n=1, 1.35%). 
There were no cases of anesthesia dolorosa or decreased corneal reflex. 
Mortality was 3% (n=2). One patient died of pneumonia 2 weeks after 
surgery. This patient was >75 years at the time of diagnosis and >90 at the 
time of surgery. One patient, age >75 years, died due to bleeding from a 
venous aneurysm of 5 × 4 mm from an AVM found at autopsy. The AVM 
was not identified in the pre-op scans. 
Clinical outcome
Mean follow-up time in TN patients was 15 months (range 1-82 
months). The initial success rate (improvement and complete recovery) 
in all TN patients was 92.1%. The overall success rate (improvement 
and complete recovery) was 88.9% calculated for the last visit of the 
patient. Initial outcome divided between typical and atypical TN is 
shown in Table 2. No patient expressed a worsening of the preoperative 
symptoms. Fourteen patients (22%) suffered from a recurrence after 
having expressed a significant improvement of their symptoms. Eight 
patients (12.7%) underwent a second MVD for their recurrence, after 
which 6 (75%) were pain-free and 1 (25%) experienced a significant 
improvement and 1 (25%) retained the same symptoms. Four 
recurrences occurred within 1 year after MVD, the other four between 
2 and 4 years. Time to reoperation was on average 2 years (range 3 
weeks-6 years). The patient that was re-operated after 3 weeks had been 
pain free for 3 days after the operation. When the patient reported a 
recurrence, the surgeon suspected a dislocation of the interposition 
material. Intraoperative, the two ventrally decompressed parallel 
arteries were still correctly decompressed. A third artery dorsal of the 
DREZ was found and decompressed consequently. 
One patient was treated afterwards by glycerol infiltration, and 
another patient rejected any further surgical treatment. High age, 
female sex and pre-treatment by glycerol or thermorhizotomy were not 
associated with worse outcome.
Duration of symptoms in TN1 patients
Shorter duration of symptoms until MVD was significantly 
associated with better final outcome in the 53 TN 1 cases as shown in 
Figure 1. Patients in the “pain free” group were operated on average 
TN 1
n=53 TN other n=10
Overall n=63 
(%)
No effect 4 1 5 (7.9)
Improvement 8 8 16 (25.4)
Complete recovery 41 1 42 (66.7)
Table 2: Initial outcome after operation.
 
Note: Patients with an unchanged pain outcome (red, n=5) were operated later 
than patients with an improved pain outcome (green, n=8) and significantly 
later than patients with a pain-free outcome (blue, n=40, *p<0.01). Two patients 
showed a pain-free outcome after 20 years of disease (2 blue dots)
Figure 1: Correlation of time to surgery and outcome.
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after 6.0 years, whilst patients in the “unchanged” group were operated 
on average 12.8 years after onset of disease (p=0.01). Mean age did not 
differ significantly (unchanged: 65.3; improved: 60.8; pain free 64.1 
years).
Discussion
Our findings add to existing body of evidence showing that shorter 
symptom duration of TN1 to MVD is significantly associated with 
a better outcome. The existing literature on this matter is either in 
agreement with our findings [11-16,19] or did not find any correlations 
[9,10,20,23-25].
As medication therapy is the first line therapy, patients are often 
referred for surgical treatment late in the course of disease. Next to that, 
duration of medication therapy is possibly prolonged as several drugs 
or drug combinations are tested and the number of possible drugs is 
still growing [26]. This leads to a delayed referral for surgical treatment 
in spite of a positive association of early MVD and better outcome. The 
association of better outcome and other surgical treatments have not 
been scope of this study as several investigations show that MVD is the 
procedure with the lowest recurrence and highest patient satisfaction 
rate [4,17,27,28]. On the other hand, medical treatment possibilities are 
limited with decreasing hepatic and renal function with increasing age 
[1]. Therefore surgical treatment can be considered a valid next-step 
option after pharmacological treatment in the elderly. Our recurrence 
rate, rate of pain relief and complication rates are similar as described 
previously in the literature [20,29-31]. Despite this recurrence rate 
75% of the patients that suffered a recurrence could be treated with a 
satisfactory outcome. 
A mortality rate of 3% is higher than described in the existing 
literature (0.5%; [32]). Both patients were elderly and had symptom 
durations of 5 and 12 years. 
Although larger series showed no significant differences in 
complications among elderly patients (0-5%; [33-35]), our mortality 
cases were >75 years of age. The unidentified AVM was most likely to 
be age-independent, however a postoperative pneumonia might have 
been avoided by another treatment option without general anesthesia 
and quicker independent mobility of the patient, e.g. radiosurgery. 
In our study many patients received medical treatment for 
10-20 years. A published comparison of medication treatment 
(carbamazepine) with MVD showed that medication treatment was less 
expensive at the beginning of the disease and that this effect faded away 
over time. In the end MVD was the cheaper option [36]. For example, 
the combination of carbamazepine with ripovacaine was already more 
expensive compared to MVD after 6 months [36]. Others predicted 
MVD to be more cost-effective after 12 months of treatment [37]. 
Unfortunately, it wasn’t possible to compare costs of surgical versus 
pharmacological treatment in our study. Although financial reasons 
should never be the main reason for a treatment-decision, financial 
factors gain in importance as costs increase and resources decline 
[38,39].
Limitations
The limitations of our study are formed by the retrospective 
character and by the small study population. Next to that the variable 
follow-up time led to a heterogeneous analysis of outcome. Reason for 
this was the health care structure of the region. Long-term follow-up 
was usually only by the doctor in their proximity. Longer neurosurgical 
follow-up could thereby mean that these patients live more in the 
proximity of the hospital or have had symptoms. Therefor a prospective 
larger registry study should be conducted. Other alternatives could be 
telephone or internet-based follow-ups. Lastly, not all essential criteria, 
defined by Zakrzewska and Lopez [40] for the structured analysis of 
treatment of TN could be met retrospectively.
Conclusion
TN patients that were operated on earlier after symptom onset have 
a better chance to a better or even pain-free outcome. Therefore, each 
patient should be informed about all treatment options, effectiveness 
and risks at an early stage of disease.
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